• Mengyao Liu and Dongyuan Zhu.
• Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
• Medicine (Baltimore). 2024 May 24; 103 (21): e38136e38136.

IntroductionInflammatory myofibroblastic tumor (IMT) is a rare invasive soft tissue tumor. Many IMTs are positive for anaplastic lymphoma kinase (ALK) with ALK gene fusion; other gene mutations have also been reported, which indicates a key role for genetic testing and the development of target therapy to optimize treatment strategies.Patient ConcernsWe report 2 patients who obtained clinical benefits following targeted treatment with ensartinib.DiagnosisThe first patient was diagnosed as IMT, with TFG-ROS1 fusion gene mutation. The second patient was IMT harboring the ALK-STRN fusion gene mutation.InterventionsWe performed gene testing for these 2 patients. According to the test result, both patients received ensartinib 225 mg QD as targeted therapy for a 30-day cycle.OutcomesThe first patient achieved partial remission and maintained a stable state for 14.7 months. The second patient was treated for 10 months and reached complete remission after 5 months and is currently still benefiting from treatment. Treatment-related side effects were mild in both patients.ConclusionOur cases provided some new insights and approaches for the clinical diagnosis and treatment of IMT.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

18 keywords...

hide…